Nanomaterials for Cancer Diagnosis and Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 20 August 2024 | Viewed by 66
Special Issue Editor
2. Department of Pharmaceutical Pathophysiology, Medical University of Gdansk, 80-210 Gdansk, Poland
Interests: nanomedicine; anticancer drugs; theranostics; nanotoxicology; biocompability
Special Issue Information
Dear Colleagues,
Multidrug resistance often necessitates the administration of high doses of anticancer drugs, leading to unintended toxicity. Nanocarriers offer a solution to this problem by actively transporting substances, such as anticancer drugs, into tumors. Nanoparticles' surface modification with biomolecules that bind specifically to cancer cells enables targeted therapy and diagnostics. Furthermore, nanoparticles serve as carriers of contrast agents in magnetic resonance imaging (MRI), and those with magnetic properties can be employed as contrast agents themselves. Additionally, nanoparticles with luminescent properties are being used in cancer diagnostics. The integration of diagnostic and therapeutic capabilities can bring many benefits, and in this regard, nanocarriers with theranostic properties demonstrate significant potential, allowing the tracking of both the location and the effectiveness of cancer treatment.
This Special Issue aims to present the current knowledge, new therapeutic and diagnostic approaches, and the application of nanomaterials in cancer therapy and diagnostics.
We welcome contributions in the form of reviews and original research articles on topics dealing with nanomaterials that may have potential applications in medicine, including but not limited to the following:
- Nanomaterials in cancer therapy and diagnostics;
- Therapeutic combination of nanomaterials;
- Functionalized nanomaterials in medicine;
- Nanocarriers;
- Study on the molecular mechanisms of anticancer nanomaterials using in vitro and in vivo models;
- Nanotoxicity of anticancer drugs.
Dr. Edyta Wysokińska
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomaterials
- anticancer drugs
- cancer diagnosis
- nanotoxicology
- biomedicine
- theranostics
- drug delivery
- surface functionalization
